Lars Wallentin

124.8k total citations · 19 hit papers
753 papers, 59.3k citations indexed

About

Lars Wallentin is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Lars Wallentin has authored 753 papers receiving a total of 59.3k indexed citations (citations by other indexed papers that have themselves been cited), including 608 papers in Cardiology and Cardiovascular Medicine, 178 papers in Surgery and 108 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Lars Wallentin's work include Acute Myocardial Infarction Research (277 papers), Atrial Fibrillation Management and Outcomes (273 papers) and Antiplatelet Therapy and Cardiovascular Diseases (222 papers). Lars Wallentin is often cited by papers focused on Acute Myocardial Infarction Research (277 papers), Atrial Fibrillation Management and Outcomes (273 papers) and Antiplatelet Therapy and Cardiovascular Diseases (222 papers). Lars Wallentin collaborates with scholars based in Sweden, United States and Canada. Lars Wallentin's co-authors include Stefan James, Bertil Lindahl, Salim Yusuf, Stuart J. Connolly, Michael D. Ezekowitz, Paul Reilly, Jonas Oldgren, John W. Eikelboom, Agneta Siegbahn and Steen Husted and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Lars Wallentin

734 papers receiving 57.0k citations

Hit Papers

Dabigatran versus Warfarin in Patients with Atrial Fibril... 2000 2026 2008 2017 2009 2009 2000 2007 2011 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dabigatran versus Warfarin in Patients with Atrial Fibrillation
    2009 8.0k citations Stuart J. Connolly, Michael D. Ezekowitz et al. profile →
  2. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
    2009 4.6k citations Lars Wallentin, Andrzej Budaj et al. profile →
  3. Markers of Myocardial Damage and Inflammation in Relation to Long-Term Mortality in Unstable Coronary Artery Disease
    2000 968 citations Bertil Lindahl, Agneta Siegbahn et al. profile →
  4. Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden
    2007 871 citations Bo Lagerqvist, Stefan James et al. profile →
  5. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
    2011 822 citations John W. Eikelboom, Lars Wallentin et al. Circulation profile →
  6. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
    2010 728 citations Lars Wallentin, Salim Yusuf et al. profile →
  7. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
    2017 659 citations Stefan James, Philippe Gabríel Steg et al. profile →
  8. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials
    2002 650 citations Robert A. Harrington, Harvey D. White et al. profile →
  9. The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
    2013 630 citations Paul Reilly, Stuart J. Connolly et al. Journal of the American College of Cardiology profile →
  10. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
    2010 582 citations Lars Wallentin, Stefan James et al. profile →
  11. The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)
    2010 570 citations Stefan James, Lars Wallentin et al. profile →
  12. Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes
    2005 515 citations Christopher P. Cannon, Lars Wallentin et al. profile →
  13. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
    2010 436 citations Christopher P. Cannon, Robert A. Harrington et al. profile →
  14. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial
    2012 422 citations Stefan H. Hohnloser, Ziad Hijazi et al. European Heart Journal profile →
  15. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease
    2016 411 citations Lars Wallentin et al. profile →
  16. Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin
    2012 399 citations Jeff S. Healey, John W. Eikelboom et al. Circulation profile →
  17. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
    2016 330 citations Ziad Hijazi, Jonas Oldgren et al. profile →
  18. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation
    2016 284 citations Ziad Hijazi, Johan Lindbäck et al. European Heart Journal profile →
  19. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014
    2017 276 citations Lars Wallentin, Claes Held et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Wallentin Sweden 114 49.4k 15.1k 14.3k 7.5k 5.6k 753 59.3k
Christopher B. Granger United States 119 49.5k 1.0× 7.3k 0.5× 13.8k 1.0× 10.0k 1.3× 5.6k 1.0× 846 63.9k
Elliott M. Antman United States 108 49.4k 1.0× 9.6k 0.6× 17.3k 1.2× 11.3k 1.5× 3.9k 0.7× 527 61.0k
Keith A.A. Fox United Kingdom 109 47.7k 1.0× 12.1k 0.8× 15.5k 1.1× 11.2k 1.5× 4.8k 0.9× 834 59.8k
John W. Eikelboom Canada 94 35.1k 0.7× 18.4k 1.2× 9.4k 0.7× 1.9k 0.2× 5.6k 1.0× 670 47.6k
Harvey D. White New Zealand 99 45.2k 0.9× 5.8k 0.4× 21.6k 1.5× 14.0k 1.9× 3.8k 0.7× 719 57.9k
Eugene Braunwald United States 127 50.8k 1.0× 8.0k 0.5× 30.6k 2.1× 12.1k 1.6× 6.7k 1.2× 703 77.3k
Philippe Gabríel Steg France 123 56.5k 1.1× 9.6k 0.6× 30.1k 2.1× 10.3k 1.4× 5.6k 1.0× 1.1k 77.2k
Eugene Braunwald United States 104 43.0k 0.9× 4.5k 0.3× 20.7k 1.4× 12.5k 1.7× 4.2k 0.7× 448 59.7k
Sabina A. Murphy United States 97 30.0k 0.6× 5.8k 0.4× 17.9k 1.2× 6.4k 0.8× 3.3k 0.6× 487 43.5k
Alan S. Go United States 93 25.3k 0.5× 4.9k 0.3× 5.6k 0.4× 3.0k 0.4× 6.5k 1.2× 483 47.4k

Countries citing papers authored by Lars Wallentin

Since Specialization
Citations

This map shows the geographic impact of Lars Wallentin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Wallentin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Wallentin more than expected).

Fields of papers citing papers by Lars Wallentin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Wallentin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Wallentin. The network helps show where Lars Wallentin may publish in the future.

Co-authorship network of co-authors of Lars Wallentin

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Wallentin. A scholar is included among the top collaborators of Lars Wallentin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Wallentin. Lars Wallentin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wallentin, Lars, Johan Lindbäck, Ziad Hijazi, et al.. (2025). Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 85(11). 1173–1185. 1 indexed citations
2.
Hijazi, Ziad, Lars Wallentin, Håkan Arheden, et al.. (2025). Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation. American Heart Journal. 290. 161–169. 1 indexed citations
3.
4.
Johnson, Linda, Alexander P. Benz, Ashkan Shoamanesh, et al.. (2024). Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient‐Level Meta‐Analysis From COMBINE AF. Journal of the American Heart Association. 13(17). e034758–e034758. 3 indexed citations
5.
Benz, Alexander P., Stefan H. Hohnloser, John W. Eikelboom, et al.. (2023). Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. European Heart Journal. 44(20). 1807–1814. 23 indexed citations
6.
Held, Claes, Nermin Hadziosmanovic, Johan Lindbäck, et al.. (2021). Risk markers of incident atrial fibrillation in patients with coronary heart disease. American Heart Journal. 233. 92–101. 6 indexed citations
7.
Millenaar, Dominic, Helmut Schumacher, Martina Brueckmann, et al.. (2021). Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). The American Journal of Cardiology. 149. 27–35. 15 indexed citations
8.
Bowman, Louise, Aris Baras, Robert M. Califf, et al.. (2020). Understanding the use of observational and randomized data in cardiovascular medicine. European Heart Journal. 41(27). 2571–2578. 21 indexed citations
9.
Hijazi, Ziad, Paolo Verdecchia, Jonas Oldgren, et al.. (2019). Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: Experiences from the RE-LY trial. IrInSubria (University of Insubria). 15 indexed citations
10.
Ducrocq, Grégory, Phillip J. Schulte, Andrzej Budaj, et al.. (2015). Balancing the risk of ischaemic and bleeding events in ACS. European Heart Journal. 36. 860–861. 1 indexed citations
11.
Armaganijan, Luciana, Renato D. Lópes, Zhen Huang, et al.. (2013). Efficacy and Safety of Vorapaxar in Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndrome : Insights From the TRACER Trial. Circulation. 128(22). 1 indexed citations
12.
Marijon, Éloi, Jean‐Yves Le Heuzey, Stuart J. Connolly, et al.. (2013). Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. Circulation. 128(20). 2192–2201. 226 indexed citations
13.
Majeed, Ammar, Hun-Gyu Hwang, Stuart J. Connolly, et al.. (2013). Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. Circulation. 128(21). 2325–2332. 209 indexed citations
14.
Hijazi, Ziad, Jonas Oldgren, Ulrika Andersson, et al.. (2012). Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. Circulation. 125(13). 1605–1616. 304 indexed citations
15.
Spall, Harriette G.C. Van, Lars Wallentin, Salim Yusuf, et al.. (2012). Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. Circulation. 126(19). 2309–2316. 112 indexed citations
16.
Connolly, Stuart J., Paul Reilly, Janice Pogue, et al.. (2012). Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years : Results of the Rely-Able Double-Blind Randomized Trial. Circulation. 126(23). 2793–2793. 6 indexed citations
17.
Wallentin, Lars, Stefan James, Evangelos Giannitsis, et al.. (2012). Abstract 15929: Outcomes with Ticagrelor Versus Clopidogrel in Relation to High Sensitivity Troponin-T in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with Early Invasive or Non-Invasive Treatment - A Substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. 126. 3 indexed citations
18.
Wallentin, Lars, et al.. (2008). Svenskt arbete med nationella riktlinjer kan bli internationellt föredöme : Med perspektiv från riktlinjerna vid hjärtsjukdom. Läkartidningen. 105(16). 2 indexed citations
19.
Dellborg, Mikael, et al.. (2000). Tolerance and safety of cangrelor, a novel purin receptor antagonist, used as a platelet aggregation inhibitor in the acute coronary syndrome. Journal of the American College of Cardiology. 35(2). 4 indexed citations
20.
Lagerqvist, Bo, Erik Diderholm, Bertil Lindahl, et al.. (2000). Coronary angiography in relation to troponin T level in patients with unstable coronary artery disease a FRISC-II substudy.. Circulation. 102(18). 2860. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christopher B. Granger Breakdown of academic impact, for papers by Elliott M. Antman Breakdown of academic impact, for papers by Keith A.A. Fox Breakdown of academic impact, for papers by John W. Eikelboom Breakdown of academic impact, for papers by Harvey D. White Breakdown of academic impact, for papers by Eugene Braunwald Breakdown of academic impact, for papers by Philippe Gabríel Steg Breakdown of academic impact, for papers by Eugene Braunwald Breakdown of academic impact, for papers by Sabina A. Murphy Breakdown of academic impact, for papers by Alan S. Go
Rankless by CCL
2026